| P/E (FY) | — | Sales (TTM) | ₹325.54B |
| Earnings (TTM) | ₹56.54B | ROE | 18.42% |
| Net Margin | 17.37% | ROIC | 19.73% |
| Debt / Equity | 0.14 | TD / EBITDA | 0.52 |
| EPS Growth 3Y | −21.79% | Sales Growth 3Y | 14.94% |
Dr. Reddy's Laboratories, with its subsidiaries, is an integrated pharmaceutical company operating in North America, Europe, India, Russia, and internationally through three segments. The Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceuticals under brand names or as generics, and engages in biologics. The Pharmaceutical Services and Active Ingredients segment manufactures and markets active pharmaceutical ingredients and intermediates and provides contract research services.
| Market Cap | — | Trading Days | 5293 |
| 52W High | 15.67 |
| 52W Low | 11.36 |
| % Off High | −25.14% |
| YTD | −16.45% | 1Y | −20.20% |
| 3Y | −9.31% | 5Y | 5.10% |
| 10Y | 64.80% | Since incept. (ann.) | 11.09% |
| Ann. Volatility (1Y) | 27.47% | Ann. Volatility (3Y) | 24.15% |
| Sharpe (1Y) | −0.70 | Sharpe (3Y) | 0.01 |
| Max Drawdown (1Y) | −26.01% | Max Drawdown (3Y) | −32.01% |
| Beta (3Y, vs SPY) | 0.10 |
| Ticker | Name | Mkt cap | P/E |
|---|---|---|---|
| LLY | ELI LILLY & Co | $1.15T | 53.2 |
| JNJ | JOHNSON & JOHNSON | $642.79B | 24.2 |
| ONC | BeOne Medicines Ltd. | $477.60B | 1739.3 |
| ABBV | AbbVie Inc. | $465.02B | 111.5 |
| MRK | Merck & Co., Inc. | $325.57B | 18.1 |
| ABT | ABBOTT LABORATORIES | $186.84B | 28.8 |
| PFE | PFIZER INC | $143.91B | 18.6 |
| BMY | BRISTOL MYERS SQUIBB CO | $129.88B | 18.4 |
| VRTX | VERTEX PHARMACEUTICALS INC / MA | $124.46B | 32.0 |
| REGN | REGENERON PHARMACEUTICALS, INC. | $65.32B | 16.8 |
| ALNY | ALNYLAM PHARMACEUTICALS, INC. | $38.25B | 123.8 |
| TEVA | TEVA PHARMACEUTICAL INDUSTRIES LTD | $36.88B | 26.2 |
